Lupus patients face roughly a 62% higher risk of developing cancer compared to the general population. That doesn’t mean 62% of people with lupus will get cancer. It means that if a certain number of cancers would be expected in a group of people without lupus, about 62% more cancers will occur in a similarly sized group of lupus patients. The absolute lifetime risk remains relatively low for most individuals, but certain types of cancer deserve closer attention.
How Much Higher Is the Overall Risk?
A large meta-analysis published in Frontiers in Oncology pooled data from multiple cohort studies and found that people with systemic lupus erythematosus (SLE) had a 62% elevated risk of developing cancer and a 52% increased risk of dying from cancer. To put that in perspective, roughly 40% of all Americans will be diagnosed with cancer at some point in their lives. A 62% increase on that baseline would push the estimated lifetime risk for lupus patients closer to the mid-to-upper 40s in percentage terms, though individual risk varies widely based on age, medications, disease severity, and other health factors.
Not all cancers are equally affected. Some are significantly more common in lupus patients, while a handful are actually less common than average.
Blood Cancers Carry the Highest Relative Risk
The sharpest increase is in blood cancers. Across studies, hematologic malignancies occur about three times more often in lupus patients than in the general population. Non-Hodgkin lymphoma stands out the most, with a roughly 4.4-fold increased risk. Hodgkin lymphoma is also elevated more than threefold. Leukemia and myeloma show meaningful increases as well, with myeloma risk more than doubled.
The connection likely traces back to how lupus behaves at the cellular level. Lupus involves chronic activation of B cells, the same immune cells that become malignant in many lymphomas. Years of abnormal immune stimulation, combined with genetic variations in DNA repair and inflammatory signaling, may push these cells toward cancerous transformation over time.
Several Solid Tumors Are Also Elevated
Beyond blood cancers, a systematic review and meta-analysis found elevated risks across several solid tumor types. Liver cancer risk is more than doubled. Cervical, lung, bladder, and thyroid cancers are each at least 50% more common. Stomach and brain cancers show more modest increases of around 30% or more.
Chronic inflammation plays a central role here. Lupus keeps the immune system in a state of persistent activation, which generates ongoing tissue damage and repair cycles. Over years, that environment can promote the kind of DNA mutations that lead to tumor growth. Certain genetic variations that predispose someone to lupus, including changes in inflammatory signaling pathways, may independently raise cancer susceptibility as well.
Some Cancers Are Less Common in Lupus
One of the more surprising findings is that several hormone-driven cancers occur less often in people with lupus. Breast, uterine, ovarian, and prostate cancers all show a lower-than-expected incidence. Melanoma risk is also reduced.
Several explanations converge to account for this. Lupus and its treatments tend to lower sex hormone levels. Women with lupus are more likely to experience delayed puberty and early menopause, both of which reduce lifetime estrogen exposure. Immunosuppressive therapies further suppress hormone production. And because lupus raises the risk of blood clots, doctors typically avoid prescribing hormonal therapies like oral contraceptives or hormone replacement, which removes another source of estrogen exposure. In men, testosterone levels tend to run lower, which may explain the reduced prostate cancer risk.
Hydroxychloroquine, one of the most commonly prescribed lupus medications, appears to offer its own protective effects. Research suggests it may inhibit cancer cell replication by suppressing an enzyme involved in cellular aging and by boosting production of a key tumor-suppressing protein. Studies have linked its use to lower rates of breast cancer and non-melanoma skin cancer in lupus patients.
Melanoma risk is likely reduced for a more straightforward reason: lupus causes severe skin sensitivity to sunlight, so most patients adopt strict sun avoidance and heavy sunscreen use, which inadvertently protects against UV-related skin cancers.
Immunosuppressive Medications Add Risk
Part of the elevated cancer risk comes not from lupus itself but from the drugs used to control it. Immunosuppressive medications work by dampening the immune system, which also weakens the body’s natural ability to detect and destroy abnormal cells before they become tumors.
Cyclophosphamide carries the most well-documented cancer risk. Because it targets healthy cells alongside immune cells, it increases the likelihood of leukemia and bladder cancer. The risk grows with higher cumulative doses and longer treatment duration, and it persists even after the medication is stopped. Chlorambucil, a related drug, is considered even more dangerous in this regard because it typically requires longer courses of treatment.
Other commonly used immunosuppressants carry their own concerns. Mycophenolate mofetil has been associated with increased lymphoma and skin cancer risk. Azathioprine raises cancer risk with long-term use. Cyclosporine is linked to higher rates of skin cancer specifically. For most patients, the benefit of controlling dangerous lupus flares outweighs these risks, but the tradeoff is real and worth discussing with a treatment team, especially for patients on these medications for many years.
What This Means for Screening
Given the pattern of elevated risks, lupus patients benefit from staying current on routine cancer screenings and may need additional monitoring. Regular cervical cancer screening is particularly important given the 50% or greater increase in risk. Patients who have taken or are taking cyclophosphamide should expect periodic urine tests to watch for early signs of bladder cancer.
For blood cancers, there is no standard screening test the way there is for breast or colon cancer. Instead, paying attention to symptoms like unexplained weight loss, persistent fevers, drenching night sweats, swollen lymph nodes, or unusual fatigue is important. These symptoms can overlap with lupus flares, which makes them easy to dismiss, so flagging any new or worsening pattern to your doctor is worthwhile.
The overall picture is nuanced. Lupus does raise cancer risk meaningfully, but the increase is concentrated in specific cancer types. For hormone-driven cancers and melanoma, the risk actually trends lower. Understanding which cancers to watch for allows lupus patients and their care teams to focus screening and vigilance where it matters most.